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INTRODUCTION 
Management of edentulous ridge with implant treatment has been 
proved to be a successful and predictable treatment for tooth loss over the past 
years(49). Mombelli. et al, stated that the two form of peri implant 
inflammation are peri-mucositis and peri implantitis (87). The early and reliable 
detection of any adverse peri implant tissue reaction is a pre-requisite for 
treatment planning in patients treated with endosseous implant and also to 
avoid future failure of implant. (Oh et al) (98). 
Alveolar bone is constantly undergoing remodelling by formation of 
new bone to compensate for the bone lost by resorption (120). This is referred to 
as coupling. In both periodontitis and peri-implantitis there is failure to form 
an equivalent amount of new bone following resorption, this is the process of 
uncoupling which has an impact on the progression of periodontal disease or 
implant failure.  
Albrektsson stated that, in dental implants the osseointegration 
occurring after the placement of the implant is a process in which the stable 
anchorage of an implant is obtained by direct bone-to-implant contact. It 
involves a series of cellular activities that closely resemble the development 
and growth of bone during embryonic and postnatal life (1). 
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Bone regeneration follows similar pathways: i.e. direct or primary 
healing, where a scaffold of woven bone, closely associated with an expanding 
vascular net, invades the granulation tissue and organizes the initially formed 
blood clot. In indirect or secondary healing, the connective tissue and/ or 
fibrocartilage differentiates within the fracture gaps and is replaced by bone as 
in endochondral ossification. Osseointegration belongs to the category of 
direct or primary healing. The final stage of osseointegration is the bone 
remodeling though this process continues throughout the life. Both the 
resorption and formation of bone around implant are coupled in a spatial and 
temporal manner. 
Extra cellular matrix plays a crucial role in bone remodelling. Alveolar 
bone consists of osteoblasts, osteocytes, bone lining cells and osteoclasts that 
are embedded in the extra cellular matrix. The extra cellular matrix of alveolar 
bone is similar to the other bone tissues, which comprises of the collagenous 
and non – collagenous proteins. Non-collagenous proteins (NCP) play a vital 
role in different steps of differentiation and activity of bone cells and in the 
maturation and mineralisation of bone matrix. Thus, the non-collagenous 
proteins of the extracellular matrix function not only in maintaining the peri 
implant homeostasis but also involved in the process of osseointegration (120). 
Among the non-collagenous proteins osteocalcin (OCN),      
osteonectin (ON), Bone sialoprotein (BSP), osteopontin(OPN) are considered 
to be the major components. 
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Osteocalcin comprises of less than 15% of the non-collagenous 
protein. It is produced by osteoblasts and is involved in the process of 
mineralisation rather than matrix production. Osteocalcin is known to be 
regulator of Hydroxyapatite crystal growth and may also recruit osteoclasts to 
sites of formed bone and is a potent marker in sites of bone turnover. Thus, 
osteocalcin is involved in both bone resorption and bone formation (110). 
Ram et al stated that, Osteonectin is a calcium binding glycoprotein 
comprising of 25% of the non-collagenous protein. Osteonectin plays a role in 
collagen turnover and enhances mineralisation of collagen matrix. Studies 
have shown the presence of osteonectin is high during developmental phases 
and also during wound healing. Implant osseointegration is a process similar 
to bone healing and osteonectin is thus considered to be important for proper 
implant stability (110). 
 The combination of clinical and radiographic parameters, such as 
probing depth (PD), BOP, suppuration of implant, mobility and marginal bone 
loss, are the commonly used parameters for the diagnosis of patients with peri 
implantitis.   However, these diagnostic processes might not be sensitive or 
specific enough to distinguish disease onset, development, and activity. 
Clinical measurements around implants as like natural teeth might be 
challenged by the force and direction of probing, implant geometry, prosthesis 
design and peri-implant soft tissue biotype. In addition, both peri-implant 
mucositis and peri-implantitis lesions can present with BOP and/or 
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suppuration, with PDs greater than 4 mm. Therefore, clinicians and 
researchers may often observe the early, and sometimes the late diagnosis of 
peri-implantitis. 
 Early detection of peri-implant destruction, as well as monitoring 
progression of bone loss is extremely important. Currently, blunt surrogate 
markers are being used such as radiographs and peri-implant probing. These 
tests have obvious limitations as they only tell us the past history of the 
disease and do not identify the present scenario or the future progression of the 
disease process. As main markers of peri-implantitis are bone destruction and 
inflammation biomarkers and enzymes in peri implant sulcus fluid (PISF), it is 
therefore essential in focusing on these entities for a precise conclusion. Such 
knowledge may potentially lead to new diagnostic strategies and candidate 
disease markers for peri-implant conditions. 
 A biomarker can be defined as an indicator of a biological state and 
can help to distinguish between normal and pathologic processes. One of the 
main advantages of evaluating biomarkers is the non-invasive nature of 
obtaining samples for analysis. Biomarkers can be measured in secretions such 
as saliva and gingival crevicular fluid (GCF), or in the case of implants which 
this particular thesis is based on, peri-implant sulcular fluid. Studies have been 
conducted to look at a vast array of biomarkers and enzymes around dental 
implants as an early sign of peri-implantitis. 
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 We have chosen osteocalcin and osteonectin for biomarker analysis 
because osteocalcin was considered to be a marker for differentiated 
osteoblasts and osteonectin is considered to be associated in the mineralisation 
process and is expressed by osteoblasts during bone formation (110). 
Hence, this study was done to evaluate the levels of osteocalcin and 
osteonectin in the PISF of healthy implant sites 6 months after loading and 
compare it to the GCF obtained from periodontally healthy sites.  
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AIM AND OBJECTIVES 
The aim and objective of the present study is: 
 
1.  To evaluate and compare the Osteocalcin levels in GCF and PISF of 
periodontally healthy tooth and implant sites. 
2. To evaluate and compare the Osteonectin levels in GCF and PISF of 
periodontally healthy tooth and implant sites. 
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REVIEW OF LITERATURE 
 
             In all multicellular organisms development is influenced by the 
interactions between cells and their extracellular matrix (ECM). ECM 
provides the cell with information about the positional and temporal clues, 
such as where it is, where it should migrate, when to differentiate, and in some 
instances, when it is time for apoptosis.  
              Mathew s et al(77) stated that ECM enhances cell recruitment through 
the  cell surface receptors called integrins, which decides the cell to ECM 
interactions and stimulate the  specific cellular functions such as adhesion, 
migration, proliferation and differentiation.ECM  is also a pool of growth 
factors such as bone morphogenic proteins (BMPs) and transforming growth 
factor (TGF)‐β1. 
             According to ellis et al, and ly et al(33), the other important feature of 
ECM is that it aids in the proteolytic degradation by proteases that in turn 
guides the tissue repair and remodelling. ECM mechanical properties are 
important to mediate and determine stem cell differentiation, besides its 
chemical composition. 
 The most important properties of ECM is its functional diversity. 
According to Robert P et al(80), all have a highly specialized functions with a 
modular design with different roles. 
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ALVEOLAR BONE:  
 Specialized part of the mandibular and maxillary bones is the alveolar 
bone which forms the primary support structure for teeth. Alveolar bone is 
subjected to continual and rapid remodelling associated with tooth eruption 
and subsequently the functional demands of mastication in comparison to the 
other bone tissues in the body.  
 During embryonic development, osteoblasts arising from condensing 
mesenchyme in the facial region that creates bony alveoli that house the 
individual teeth of the developing dentition forms the intra membranous bone 
of the maxilla and mandible (120). In three dimensions, these osteoblasts form 
an extensively perforated sheet of otherwise contiguous osteoblasts which, not 
only produces the alveolar bone matrix proper, in addition they embed 
continuously remodelling periodontal ligament fibers in a precise manner (62). 
 it is followed by the maturation and then the osteoblasts may undergo 
apoptosis or embed in the matrix as osteocytes or remain on the bone surface 
as bone lining cells.  
 Osteoblasts that transformed to osteocytes occupy spaces (lacunae) in 
bone and are termed as cells surrounded by bone matrix. Important factor is 
the ability of bone to respond to biological regulatory factors and functional 
forces is the capacity of the large, multinucleated osteoclasts to resorb 
bone(120). An extensive homeostatic network of cells formed together with 
osteocytes, bone-lining cells and their connecting cell processes capable of 
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regulating plasma calcium concentration through mechanisms partly 
independent of those related to the bone remodelling system (79). 
ALVEOLAR BONE ECM: 
 The osteoblasts synthesis bone matrix in two main steps: deposition of 
organic matrix and its subsequent mineralization. In the first step, the 
collagenous proteins, mainly type I collagen, non-collagen proteins (OCN, 
osteonectin, BSP II, and osteopontin), and proteoglycan including decorin and 
biglycan, which form the organic matrix are secreted by the osteoblasts. Then 
the mineralization of bone matrix occurs. 
 60% inorganic, and 40% organic compounds (40%) makes up the 
alveolar bone. The hydroxyapatite crystals are formed by the nucleation of the 
calcium and phosphate ions, which are represented by the chemical formula 
Ca10(PO4)6(OH)2. Along with collagen, the non collagenous matrix proteins 
form a scaffold for hydroxyapatite deposition and such correlation is 
responsible for the typical stiffness and resistance of bone tissue (79). 
 Clarke(24) also stated that the organic phase is made up of 90% of 
collagen type I and10% of mineral binding non‐collagenous proteins (NCP) 
such as glycoproteins, gamma carboxy‐glutamic acids, proteoglycans, and 
osteogenic proteins such as BMPs and TGF.  
 Collagen is the most unique ECM protein and is designed in such a way to 
to provide structure and resiliency to tissues (81). 
 Morgan et al and Roach et al(90,116) said that non collagenous protein 
such as bone sialoproteins(BSP), osteocalcin( OC), osteonectin, osteopontin( 
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OPN) and proteoglycans such as decorin and biglycan containing a protein 
nucleus with side- chains of glycosaminoglycans including chondroitin 
sulfate( CS) and hyaluronic acid, controls bone mineralization and  bone mass. 
Hydroxyapatite and collagen type I both binds with BSP and Addison et al (4) 
said that OPN mediates the growth of hydroxyapatite crystals, and promotes 
the osteoclasts attachment onto the inorganic structure of bone.   
The association between the bone formation and the bone resorption 
maintains the bone mass .Formation of bone, involves the proliferation and 
differentiation of stromal stem cells along an osteogenic pathway that leads to 
the formation of osteoblasts. Osteogenic line of cells give rise to 
preosteoblasts, osteoblasts, osteocytes, and bone lining cells, which, in turn, 
derived from the primitive mesenchymal cells in bone marrow stroma and 
from pericytes adjacent to connective tissue blood vessels.  
Differentiation of these osteogenic cells   requires activation of the 
Osf2/Cbfa gene, which initiates the expression of osteocalcin, bone 
sialoprotein (BSP), osteopontin (OPN), and collagen synthesis, which is 
followed by stimulation from bone morphogenetic protein- (BMP-) 2 and 
transforming growth factor beta (TGF-𝛽)(112,116). 
 According to Glowacki et al(40), the osteocalcin promotes the 
recruitment and attachment of osteoclast precursor to bone matrix and 
promotes them to   differentiate to osteoclasts. Venkatesh B et al(132) said that, 
the absence of non-collagenous proteins, especially small integrin‐binding 
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ligand N‐linked glycoproteins (SIBLINs) prevents ossification in vertebrates, 
which highlights their significant role in bone formation. 
Both structural and biological functions are served by bone ECM, as 
the tissue’s mechanical properties are achieved by the mineralized matrix, 
while it also provides chemical cues that regulate bone cells and acts as a 
reservoir for ions. ECM– integrin bonds that enable the formation of adhesive 
structures and activate signalling pathways, which regulate cell spreading, 
survival, and differentiation are regulated by the bone ECM. 
Thus, bone matrix comprises of a complex and organized framework 
that provides mechanical support and plays an important role in the bone 
homeostasis. Several molecules that interfere in the bone cells activity and, 
consequently, has a participation in the bone remodeling are secreted by the 
bone matrix (41). 
Interactions between Bone Cells and Bone Matrix 
  As mentioned earlier, bone matrix not only provides support for bone 
cells, but also plays a significant role in regulating the activity of bone cells 
via several adhesion molecules (41,144). The most common adhesion molecules 
involved in the interaction between bone cells and bone matrix are the 
integrins (142). 
  Integrins aid osteoblasts to interact with bone matrix, which recognize 
and bind to RGD and other sequences present in bone matrix proteins 
including osteopontin, fibronectin, collagen, osteopontin, and bone 
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sialoprotein (27,76).  𝛼1𝛽1, 𝛼2𝛽1, and 𝛼5𝛽1 are the common integrins present in 
the osteoblast (48).  During osteoid synthesis these proteins play a key role in 
osteoblast organization on the bone surface (142). 
In addition, the interaction between osteoclasts and bone matrix is 
essential for osteoclast function, because the bone resorption occurs only when 
osteoclasts bind to mineralized bone surface (113). Thus, 𝛼v𝛽3 and 𝛼2𝛽1 
integrins expressed by the osteoclast during bone resorption to interact with 
the extracellular matrix, in which the former bind to bone-enriched RGD-
containing proteins, such as bone sialoprotein and osteopontin, whereas 𝛽1 
integrins bind to collagen fibrils (47,48). 
Stimulation of the osteoclast activation occurs after binding of 
RANKL to its receptor RANK, present in the membrane of osteoclast 
precursors. Osteoclast becomes polarized by reorganizing its cytoskeleton; the 
ruffled border (RB) and clear zone (CZ) are membrane specializations 
observed in the portion of the osteoclast proximal to the bone resorption 
surface, Howship lacuna (HL) (35).  
The osteoclast initiates acidification due to pumping of hydrogen ions 
(H+) to the HL. H+ ions and bicarbonate (HCO3 −) derived from the cleavage 
of carbonic acid (H2CO3) under the action of carbonic anhydrase II (CAII) and 
causes the dissolution of the hydroxyapatite which present proximal to the 
ruffled border. Cathepsin, matrix metalloproteinase-9 (MMP-9), and tartrate-
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resistant acid phosphatase (TRAP) that degrade the organic matrix are released 
by the osteoclast, following the dissolution of hydroxyapatite. 
Then the EphrinB2 (Eph2) present in osteoclast membrane binds to 
ephrinB4 (Eph4) in osteoblast (Ob) membrane, which mediates its 
differentiation, whereas the reverse signalling (ephrinB4/ephrinB2)    inhibits 
osteoclastogenesis. Osteoblasts are inhibited by Sema4D, which is produced 
by osteoclasts, while Sema3A produced by osteoblasts inhibits osteoclasts. 
Osteoblasts (Ob) also forms receptor activator of nuclear factor KB (RANKL) 
and osteoprotegerin (OPG), which promotes and decrease osteoclastogenesis, 
respectively (35).                       
Thus the activated osteoblasts secrete collagenous (Col1) and 
noncollagenous proteins such as osteocalcin (OCN), osteopontin (OSP), 
osteonectin (OSN), bone sialoprotein (BSP), and bone morphogenetic proteins 
(BMP) are produced by these activated osteoblast.   
Osteocytes are located within lacunae surrounded by mineralized bone 
matrix  crosses  canaliculi with its cytoplasmic process  to make connection 
with other neighbouring osteocytes processes by gap junctions, mainly 
composed by connexin 43 (Cx3), as well as to cytoplasmic processes of 
osteoblasts  and bone lining cells (BLC) on bone surface. 
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 Osteoclastogenesis is stimulated by the RANKL secreted by 
osteocytes, while the osteoblastic activity is stimulated by the prostaglandin 
E2 (PGE2), nitric oxide (NO), and insulin-like growth factor (IGF). On the 
other hand, osteocytes secrete OPG that inhibits osteoclastogenesis; moreover, 
osteocytes produce sclerostin and dickkopfWNT signalling pathway inhibitor 
(DKK-1) that decrease osteoblast activity (35). 
 
 
ALVEOLAR BONE HOMEOSTASIS: 
            Bone is markedly an active and dynamic tissue, which undergoes 
constant renewal in response to mechanical, nutritional, and hormonal 
influences. A prerequisite for the regeneration of tissues lost through 
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periodontal disease and for osseointegration of implants is the formation of the 
alveolar bone.  
             An equilibrium between the coupled processes of bone resorption by 
osteoclasts and bone formation by osteoblasts is required for a healthy 
periodontium (16,126,127). Under physiologic conditions, the above said processes 
are very carefully controlled by systemic hormones and local factors and 
orchestrated by osteocytes and bone lining cells which fine-tune interstitial 
fluid and plasma calcium levels. 
               A strong similarity between the cellular and molecular events 
involved in bone remodelling and inflammation & repair is seen, and the 
relationships between matrix molecules, such as osteopontin, bone 
sialoprotein, SPARC and osteocalcin, and blood clotting and wound healing 
are clearly evident. The bone remodelling cycle operates continually as 
osteoclasts are constantly resorbing the mature bone, with new bone 
simultaneously formed by osteoblasts (128). This multistep process occurs in 
four distinct phases of activation, resorption, reversal, and formation.  
Initiating event that converts a resting bone surface into a remodelling 
surface is defined as activation (127,7). This involves the recruitment of 
mononuclear osteoclast precursors to the bone surface, differentiate and fuse 
into functional osteoclasts (135). Terminal differentiation and mononuclear cell 
fusion is controlled by cell-to-cell interactions between osteoclast progenitors 
and osteoblasts/stromal cells and by contact with the mineral phase, 
particularly with osteocalcin (4,131). 
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Non mineralized osteoid encasing the mineralized bone matrix must be 
dissolved before the osteoclasts can attach to the mineralized matrix and 
initiate resorption (134). Following this process, the activated osteoclasts attach 
to the bone matrix and reorganize the cytoskeleton; and uptake a polarized 
morphology, forming a sealed zone to isolate the resorption site and develop 
ruffled borders which secrete protease enzymes.  
During the “resorption” phase, osteoclasts work in an environment 
which removes both mineral and organic components of the bone matrix. 
Howship’s or resorption lacuna, which is the erosion of the scalloped 
appearance, is the hallmark of the resorbing surface. 
There is a “reversal” phase, marking the transition from destruction to 
repair after most of the mineral and organic matrix has been resolved. Here, 
the coupling of resorption to formation takes place. The osteoclast can move 
along the bone surface and restart resorption or undergo apoptosis, after the 
completion of one resorption lacuna (128).  
During resorption by the acidic environment created by osteoclasts the 
coupling factors are released from their binding proteins, and through the 
negative feedback they further inhibit resorption, by suppressing osteoclast 
formation and initiating osteoblastogenesis (39). Thus, in a series of events 
which is locally controlled autoregulated cell activation, osteoclastic 
resorptive phase is usually follows a “repair phase” (39). 
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 A cascade of differentiation events occurs including chemotaxis, cell 
attachment, mitosis, and differentiation of osteoblast precursors takes place, 
leading to new bone deposition, during repair (39).  
  Two theories generally clarify how calcification proceeds: the matrix 
vesicle theory and the nucleation theory; it is speculated that both theories 
work in parallel depending on the type of skeletal tissue involved (127). After 
the mineralization process is initiated, the mineral content rapidly upregulates 
over the first few days to 75% of final mineral content, taking up to a year for 
the matrix to reach maximum mineral content. The important constituent of 
the mature mineral phase is hydroxyapatite (39). 
Matrix mineralization requires, cellular adhesion, and regulation of cell 
activity for coupling of formation and resorption to occur and for this, the   
non-collagenous bone matrix proteins play a key role. Osteocalcin, one of the 
most abundant of these proteins, has a prominent role in mineralization, it acts 
as a chemoattractant, and may be crucial for osteoclast differentiation. Bone 
sialoprotein (BSP), a highly specific bone protein, has high calcium-binding 
potential, thus inhibiting mineral deposition.  
It also initiates the adhesion of osteoclasts to bone matrix molecules 
through the key RGD (arginine-glycineaspartic acid) peptide sequence and 
controls the osteoclast formation. Osteopontin and osteonectin too are primary 
in osteogenic cell activity (39). 
The osteoclast activation and differentiation are regulated by three 
members of the TNF ligand and receptor superfamilies: the osteoclastogenesis 
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inducers RANKL, RANK, and OPG. RANKL (receptor activator of nF-𝜅B 
ligand) is a member of the TNF superfamily   
             Osteoprotegerin (OPG), its decoy receptor, is a circulating protein, 
produced by a variety of cell types including osteoblasts and marrow stromal 
cells, which inhibits osteoclast formation by binding mRANKL, thereby 
preventing the stimulatory cell-to-cell interaction with preosteoclasts and 
inhibiting RANKL/RANK interactions. Hence, these three proteins are 
important for osteoclast differentiation directed by osteoblasts, and the balance 
between RANKL and OPG in osteoblasts directs new osteoclast recruitment 
(93,100,52). 
           In periodontal disease, the RANKL is produced by the T cells present 
in the gingival tissues.  Lytic enzymes like TRAP, are present abundantly in 
the fully matured osteoclast, these enzymes cause the demineralization of the 
mineralized tissues which leads to bone resorption and activation of the 
osteoinductive factors like BMP. The Cbfa1 and other genes which initiates 
osteoblasts activation and differentiation and lead to bone formation are 
activated by the BMP(51). 
 
          The presence of the periodontal pathogen leads to the production of 
proinflammatory cytokines, such as TNF-α and IL1β, which stimulate 
expression and activation of matrix metalloproteinases (MMPs) that degrade 
extracellular connective tissue matrix (51).  
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Osteoclastogenesis can be independently stimulated by the cytokines such as 
TNF-α while other cytokines stimulate RANKL expression that leads to 
formation of osteoclasts and osteoclast activity. The high levels of 
inflammation and bone resorption are led by the combined innate and adaptive 
immune responses. These proinflammatory cytokines are thought to produce 
an amplification loop that contributes to periodontal and peri implants disease 
progression (51). 
BONE TO IMPLANT: 
 Endosseous dental implants are widely placed in maxillae and 
mandibles as an alternate for teeth in to restore or replace function in partially 
or completely edentulous patients. Following the functional loading of dental 
implants, the process of osseointegration occurs (13). 
 Various factors such as implant surface, anatomical site, surgical 
trauma, time of specimen observation plays a pivot role to the tissue response 
giving rise to osseointegration (131). When inserting an implant into the 
ostectomy site a sequence of different biological events occurs at the bone-
implant interface until the implant surface is fully covered with a newly 
formed bone. 
 In an orchestered manner cell types, tissues, growth factors and 
cytokines are involved during the inflammatory, formation and remodelling 
phases of bone healing. This indicates that osseointegration should be 
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regarded not as an exclusive reaction to a specific implant material but as the 
expression on the endogenous basic regenerative potential of bone (100). 
 The first clinical outcome of surgical procedures is the primary 
stability of the implant, which consists of a rigid fixation of the implant within 
the host bone cavity together with absence of micro-motion of the implant (39).
 A fibrous membrane formation around the implant occurs if there is an 
excessive mobility present and cause displacement at the bone-implant 
interface inhibiting osseointegration (32). 
 A close approximation between implant and host bone may impede 
osteogenesis because in these areas there is no evidence of early bone 
formation. In contrast, space more than 500 mm predicts a reduction in the 
quality or quantity of the newly-formed bone and delay the rate of gap 
filling(42). So a high quality bone seems to be important for the primary 
stability of implant. 
MECHANISM OF OSSEOINTEGRATION: 
 The principle mechanism of the osseointegration around implants are 
very similar to those occurring during bone fracture repair and involve a series 
of various cellular and extracellular events (44). The initial host response after 
implant placement is characterized by an inflammatory reaction elicited 
mainly by the inevitable surgical trauma and modified by the presence of the 
implant.  
Review of Literature 
 
 
24 
 
 Immediately after the surgical procedure the bone walls are rapidly 
covered with blood, hence it is the first tissue coming into contact with the 
implant surface after the implant is positioned in the bone cavity. 
Inflammatory cells, primarily polymorphonuclear granulocytes, and later 
monocytes, emigrate from post-capillary venules and migrate into the tissue 
surrounding the implant.,  
 Proteins are adsorbed from blood and tissue fluids, after the blood 
comes into contact with the implant surface. Oxidation of the metallic 
implants occurs in both in vitro and in vivo (86). Then the inflammatory cells 
respond after stimulation by secretion of proteins with effects on 
inflammation, bone healing and immune reactions evokes an response by 
several of the inflammatory cells detected at the interface. The structure and 
physiochemical properties of the implant surface are altered by these products.  
STAGES OF OSSEOINTEGRATION:  
 Osseointegration follows a common, biologically determined program that 
is subdivided into 3 stages: 
Incorporation by woven bone formation, followed by adaptation of bone mass 
to load (lamellar and parallel-fibered bone deposition); and then the adaptation 
of bone structure to load (bone remodelling). 
 Osteoblasts begin to deposit collagen matrix directly on the early formed 
cement line/lamina limitans layer described on the implant surface, after a few 
days of implantation (3). In the peri-implant environment early bone formation 
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is the result of an appositional process on the cement line/lamina limitans 
holding onto the solid surface of the implant.   
            The osteoblasts cannot always migrate so rapidly to avoid being 
completely enveloped by the mineralizing front of calcifying matrix and thus 
they become clustered as osteocytes in bone lacunae. An appositional process 
on the cement line/lamina limitans holding onto the solid surface of the 
implant results in the early bone formation in the peri implant environment. 
             Following the early deposition of new calcified matrix on the implant 
surface, the arrangement of the woven bone and bone trabeculae developing in 
three dimensional directions and delimiting marrow spaces occurs (84). 
               This tissue consists of woven bone, cancellous bone or trabecular 
bone and is particularly suitable for the implant healing process as it shows a 
very active wide surface area, contiguous with marrow spaces including many 
vessels and mesenchymal cells (84). 
              The healing calcified tissue which can fill the gap between implant 
and bone more rapidly, and offer a mechanical resistance to loading thanks to 
its three-dimensional structure (a network of bone trabeculae arranged in 
arches) is defined as the trabercular bone.  In two different directions                 
peri-implant osteogenesis consists in woven bone and trabecular bone 
formation proceeds i.e., from the host bone towards the implant surface 
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(distance osteogenesis) and from the implant toward the healing bone (contact 
osteogenesis)(73). 
  Wound maturation around implants occurs like normal and 
physiological bone adaptation in the skeleton through the modelling and 
remodelling mechanisms, the two primary mechanisms by which bone at the 
interface can adapt to mechanical loading, are thought to be accountable for 
reshaping or consolidation of bone at the implant site. In cortical, as well as in 
cancellous bone, remodelling occurs in discrete units, often called a bone 
multicellular unit, as proposed by Frost. 
  Remodelling starts with osteoclastic resorption, followed by lamellar 
bone deposition. Resorption and formation are coupled in space and time. This 
process usually initiates as an outcome of a fatigue damage to bone and 
involves four different processes: osteoclasts activation, bone resorption, 
osteoblasts activation, and finally mineralization of new bony tissue (15). 
  Bone remodelling is a multifaceted process involving not only 
interactions between cells of the osteoblastic lineage and bone matrix proteins, 
but also a numerous systemic and local regulatory factor are involved 
(Dempster, 1995). The cells of bone coordinate their proliferation and 
activities by the expression and response to hormones (PTH), and cytokines 
(IGFs, TGF-b1, FGF, BMP, EGF, PDGF, etc) (65). 
  Remodelling in the third stage of osseointegration contributes to an 
adaptation of bone structure to load in two ways: 
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1. It improves bone quality by replacing pre-existing, necrotic bone 
and/or initially formed, more primitive woven bone with mature, 
viable lamellar bone. 
2. It leads to a functional adaptation of the bone structure to load by 
changing the dimension and orientation of the supporting elements. 
           It has been mentioned already that bone remodelling continues 
throughout life and thus becomes important for the longevity of implants. 
 
BIOMARKERS: 
A substance indicating a biologic state is termed as a biomarker. It is 
defined as, a substance that is measured objectively and evaluated as a 
measure of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention. 
 Detection of disease activity and treatment outcome non-invasively 
could be the most desirable goal in health cause promotion and delivery. Oral 
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fluid biomarkers that have been studied for periodontal diagnosis include 
proteins of host origin (e.g., enzymes and immunoglobulins), phenotypic 
markers, host cells (e.g., PMNs), hormones, bacteria and bacterial products, 
ions, and volatile compounds (60). 
 Because of the complex, complex nature of periodontal disease, it is 
undesirable that a single biomarker will prove to be a stand-alone measure for 
periodontal disease diagnosis. More probable the invention of an oral fluid-
based diagnostic using a combination of host- and site-specific markers that 
accurately assess periodontal disease status (60). 
 There are no dependable tests to diagnose and predict progression of 
periodontitis, present currently. Although clinical diagnosis of periodontitis 
based on visual and radiographic assessment in addition to measurement of 
pocket depth, tissue attachment, and “bleeding on probing” (BOP) in different 
locations in multiple teeth is well established in dental practice, but they 
demand time from the periodontist (114). 
There is a need for tests that tell the clinician more than the 
conventional diagnostic tools at his/her disposal, for example, visual changes, 
clinical assessment (e.g., BOP), and radiographs; these traditional diagnostic 
procedures give an indication of severity and, therefore, may reflect disease 
occurred but not current disease activity and they do not identify susceptible 
individuals who might be at risk of future periodontitis (103).  
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For effective clinical management of periodontitis, the application of 
scientific evidence and patient-specific information is now considered to be 
central (60). Clinical mismanagement occurs due to lack of evidence-based 
knowledge of individual patients’ disease, for example, failure to identify 
disease activity and inappropriate antimicrobial therapy.  
The need for a dependable biomarker to distinguish progressive 
periodontitis from normal biological processes is considered essential to 
identify periodontitis at an earlier or even preclinical stage, to initiate 
preventative pretreatment, and also to conduct epidemiological studies (60). 
For studying bone metabolism in population studies biochemical 
markers of bone turnover have proved to be a useful, non-invasive and 
relatively an inexpensive tool and it is also gradually becoming established in 
clinical practice.  However, they are used mainly in monitoring response to 
treatment. 
 Increase in the knowledge of the pathophysiology of periodontitis can 
be obtained due to the continued development of new markers of bone 
turnover. The continued development of new markers of bone turn over will 
increase the knowledge of pathophysiology of periodontitis and metabolic 
bone diseases like osteoporosis. After further evaluation these markers may 
find a place in the clinical case of post-menopausal women. 
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 For risk assessment and comprehensive screening of biomarkers, new 
diagnostic technologies such as microarray and microfluidics are available 
now. For the detection of clinical biomarkers electrochemical biosensors 
coupled to Magnetic Beads are used. A way for better treatment approaches to 
periodontal disease can be obtained from the recent advances in biomarkers   
Parallel with better understanding of biochemical processes in bone 
and isolation and characterization of cellular components of skeletal matrix, 
the number of new potential biochemical markers of bone formation and 
resorption is found. Generally, markers are classified into the following        
groups (60). 
a. Enzyme activity markers of bone formation (connected with osteoblast 
activity) and of bone resorption (connected with osteoclast activity); 
b. Bone matrix proteins and resorption products of organic skeletal 
matrix, which are secreted into circulation during bone formation and 
resorption; 
c. Inorganic skeletal matrix markers (calcium, phosphorus which, above 
all, reflect calcium-phosphorus homeostasis). 
  The continued development of new markers of bone turn over will 
enhance the knowledge of pathophysiology of periodontitis and other 
metabolic bone diseases like osteoporosis. After further assessment these 
markers may find a place in the clinical case of post-menopausal women 
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 During the past decade a considerable attention have been gained on 
biomarkers of disease. These markers generally fall into three categories: 
1. Indicators of current disease activity; 
2. Predictors of future disease progression; 
3. Predictors of future disease initiation at currently healthy sites. 
  The potential biomarkers in the GCF have been grouped into three 
general categories 
❖ Host-derived enzymes 
❖ Inflammatory mediators and products 
❖ Tissue-breakdown products 
 For risk assessment and comprehensive screening of 
biomarkers new diagnostic technologies such as microarray and 
microfluidics are now currently available. For the detection of clinical 
biomarkers Electrochemical biosensors coupled to Magnetic Beads are 
used. These recent advances in biomarkers and diagnostic tools could 
prove a way for better treatment approaches to periodontal disease 
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CONNECTIVE TISSUE BREAKDOWN PRODUCTS AS BIOMARKERS 
A prospect of determining the metabolic or structural state of the tissue 
is represented by the identification of tissue-specific structural molecules in 
oral fluids derived from periodontium. 
     Mature intermolecular cross links of collagen are pyridinoline and 
deoxypyridinoline, they are released upon osteoclastic bone resorption and 
collagen matrix degradation. It is specific to alveolar bone hence it is 
considered as a potential marker of bone turnover. 
 Kunimatsu K et al(60) reported that, osteocalcin was absent in the 
GCF of the gingivitis patient whereas they were predominantly present in the 
periodontitis patients, thus they were the indicators for the periodontal disease 
progression. 
       “On the assessment of the  combination of the biochemical markers 
osteocalcin, collagenase, prostaglandin E2, 𝛼2-macro-globulin, elastase, and 
alkaline phosphatase, a significant diagnostic sensitivity and specificity values 
of 80% and 91%, respectively, were reported” by Nakashima et al.                 
In 1996(94). 
         Zung P et al(145) postulated that in the presence of active osteoblast 
bone formation markers are increased though its actual functions are not clear.  
Kuminastu et al (1993)(61) demonstrated a positive correlation 
between amino terminal peptide, GCF osteocalcin and clinical parameters in a 
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cross sectional study with gingivitis and periodontitis patients. Also, 
osteocalcin was not detected in patients with gingivitis (61). 
Ng PY et al (2007)(95) showed that with bone-loss scores in patients 
with periodontal disease are inversely proportional to the salivary levels of 
osteocalcin and osteonectin.  
Smith AJ et al (1997)(119) suggested a positive correlation have been 
made with glycosaminoglycan levels and periodontal pathogens such as                   
P. gingivalis. 
 
OSTEOCALCIN AND OSTEONECTIN 
Osteocalcin: 
           Osteocalcin is a non – collagenous calcium binding protein which is 
present enormously in the calcified tissues. 
        Osteocalcin, the most abundant non-collagenous protein of mineralized 
tissues is also called as bone Gla-protein is composed of 15% of non-
collagenous proteins.  It is a small (5. 4kDa) calcium binding protein of bone 
and is a protein with a molecular mass of approximately 6kd, containing 49 
aminoacids.  
Osteocalcin is predominantly secreted by osteoblasts, odontoblasts and 
hypertrophic chondrocytes and it plays an important role in both bone 
mineralization and resorption.    
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 Immunohistochemically demonstrated their presence in the alveolar 
bone, highly conserved protein that is 5.8-kDa characteristically modified by 
vitamin K–dependent carboxylating enzymes that convert two to three 
glutamic acids into g-carboxyglutamic acids (gla groups)  
The promoter region of the osteocalcin gene has been extensively 
characterized for its transcriptional regulation and the tissue-specific 
expression in which the runt domain transcription factor and osteoblast-
specific transcription factor cbfa1 are directly implicated. The gla groups 
formed on the pro-osteocalcin prior to secretion bind calcium ions strongly 
increase the affinity of osteocalcin for bone mineral. A predicted spacing of 
the gla groups in an α-helical conformation corresponds to the 0.545 nm 
spacing of the calcium ions in the 001 plane of the hydroxyapatite crystal. 
It involves in recruiting osteoclasts to sites of newly formed bone and 
function as a regulator. During periods of rapid bone turnover serum 
osteocalcin levels are increased. A valid marker of bone turnover when 
resorption and formation are coupled is osteocalcin and also a specific marker 
of bone formation when formation and resorption are uncoupled. 
Osteocalcin and osteocalcin fragments are likely to be released from 
the extracellular matrix into the GCF, during active bone resorption.  
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   A pathology in bone metabolism can be determined by the changes in 
the measure of the bone protein and thus osteocalcin can be used as a potent 
clinical diagnostic marker [Ram VS et al, 2015] (110).  
  Kunimatsu K et al(60) reported that, osteocalcin was absent in the in 
the GCF of the gingivitis patient whereas they were significantly present in the 
periodontitis patients, thus indicates their role as predictors for the periodontal 
disease progression. 
 Studies have reported that the levels of osteocalcin are proportional to 
the disease progression. Several studies reveal about the role of osteocalcin in 
PCF of subjects with periodontitis (21–23). Using a limited number of 
endosseous implants, Murata et al.(91) presented that osteocalcin in the GCF 
may reflect an enhanced bone turnover around oral implants, and PISF 
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osteocalcin levels in sulcular fluid of implants with gingivitis were 
significantly upregulated than the healthy ones.  
Nakashima et al. In 1996(94) reported a “significant GCF osteocalcin 
levels from gingivitis and periodontitis patients.” “On evaluation of a 
combination of the biochemical markers osteocalcin, collagenase, 
prostaglandin E2, 𝛼2-macro-globulin, elastase, and alkaline phosphatase, 
enhanced diagnostic sensitivity and specificity values of 80% and 91%. 
Masashi Murata (91) stated that increased levels of GCF osteocalcin 
from periodontitis sites may be related to the sensitivity of alveolar bone 
resorption and/or repair. PISF osteocalcin levels showed a tremendous 
difference between peri-implant mucositis and healthy implants, although 
there were no significant differences between peri-implantitis and other sites. 
Murata et al.(91) also  reported that osteocalcin  was a factor of 
osteoblast activity and bone formation as well as bone resorption, and serum 
osteocalcin levels achieved from peri implantitis sites, peri-implant gingivitis 
(mucositis) sites and peri-implant healthy sites did show any significant 
difference and all osteocalcin serum levels were in normal limits. Osteocalcin 
seemed to be a more consistent marker of oral implant bone destruction. 
Onder gurluk(43) said that smoking seems to decrease salivary 
osteocalcin level but ICTP levels were not affected by smoking. This 
suppression in OC levels may be one mechanism of deteriorating effects of 
smoking on periodontal health. the serum concentration of OC could also be 
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used as a marker for bone formation (Price 1985; Hoffmann et al. 1996). This 
was also confirmed in this study, where serum concentrations of OC were 
higher in patients taking Pamidronate has alveolar remodelling where higher 
in such patients. 
Cakal OT(17)  said  that  Soft tissue inflammation around dental 
implants does not cause a variation in osteocalcin, osteopontin, and 
osteonectin levels in PISF. Also, peri-implantitis does not seem to give rise to 
an increase in PISF levels of osteocalcin, osteopontin, and osteonectin. 
             Through the results of various studies in the past it is determined that 
the alveolar bone extracellular matrix proteins ostenectin and osteocalcin are 
involved in bone remodelling and in osteogenesis. 
Osteonectin: 
The principal extracellular matrix (ECM) protein in cementum, bone, 
and PDL is the type I collagen, an appreciation of cellular mechanisms that 
control collagen assembly and deposition in these tissues is important to 
improve treatments that enhance regeneration. For the formation of collagen 
fibrils and fibers collagen undergoes postsynthetic processing in the 
extracellular space (110). 
 For the collagen fibril synthesis, collagen fiber assembly and the 
deposition of collagen into the ECM collagen-binding proteins are essential. 
Secreted Protein Acidic and Rich in Cysteine (SPARC)/Osteonectin is a 
collagen binding protein with a profound effect on ECM structure and content. 
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It is also referred to as basement membrane protein (BM-40).  Osteonectin 
is a single-chain polypeptide that binds strongly to hydroxyapatite and other 
extracellular matrix proteins including collagens. Osteonectin is composed of 
25% of the non-collagen proteins. 
The gene encoding SPARC/osteonectin is predicted to produce a                  
33-kDa protein which further undergoes post translational glycosylation so 
that secreted SPARC/ osteonectin protein is 43 kDa in most tissues. SPARC/ 
osteonectin is a matricellular protein, that binds to collagen through the Ca21 
extracellular domain in the C terminal portion of the protein (110).  
Osteonectin is a de-adhesion matricellular protein which aids the 
cell to move from a state of strong adherence to a state of weak adherence, 
which is also deemed necessary as this feature helps in the migration of the 
cells towards the implant, which in turn aids in the osseointegration and bone 
remodelling. Osteonectin is one such important matricellular protein that aids 
the cells to stay in spreaded morphology, antagonizing the pro-adhesive 
activity of other matrix proteins, which is very essential for cell proliferation 
occurring during any cellular injury (93). 
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During embryogenesis they are widely expressed, and in vitro studies 
have suggested their roles in the control of cell adhesion and proliferation, and 
in the modulation of cytokine activity. SPARC can bind to thrombospondin 1 
and collagen, although the collagen-binding site is cryptic, lying between two 
a-helices and exposed by proteolysis (17).  
Studies of primary fibroblasts reveals that the osteonectin in 
pericellular processing of procollagen, and a function in collagen turnover at 
the cell surface has been proposed.  Both a collagen-binding domain and an 
hydroxyapatite binding region are resent in osteonectin. 
Osteonectin has been implicated in the early phases of tissue 
mineralization because of its affinity for collagen and hydroxyapatite. In the 
osteoid, SPARC has been proposed to bind to the collagen and hydroxyapatite 
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crystals and they release calcium ions perhaps enhancing mineralization of the 
collagen matrix in bones (11).  
In addition to collagen binding, SPARC have been attributed to several 
additional activities. For example, the extracellular domain was shown to 
regulate anti proliferative and counter adhesive activities in cells in culture 
(2;3; 4; 5). Interactions between the cell and ECM is modulated by the 
osteonectin and they also influence the efficacy of certain growth factors (6).  
Expression of osteonectin is found to be more significant during the 
development of the tissues, and re-expression of SPARC/osteonectin is 
frequently associated with ECM remodelling events such as wound healing (7).   
Studies have shown that the activity of osteoblasts and osteoclasts are 
regulated by osteonectin; the two primary cell types regulating bone 
homeostasis and repair. Osteoblasts undergoing active matrix deposit express 
osteonectin. 
Levels of osteonectin protein are at the peak at times coinciding with 
initial stages of differentiation and subsequently they down regulate as cells 
mature and begin to express mature osteoblastic markers. 
Ram VS et al, 2015(110) have reported that the osteonectin, a non-
collagenous protein in the bone matrix, aids in the cell matrix interaction in the 
remodelling tissues and it is produced by the osteoblast, endothelial cells and 
fibroblast.  
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Zung P et al(145) postulated that it is a bone formation marker 
enhanced in the presence of active osteoblast though its actual functions are 
not clear. 
  In a cross-sectional study by Bowers et al(14). From patients with 
gingivitis, at moderate or severe periodontal disease states GCF’s samples 
were analyzed. Using a dot blot assay, it was analyzed that both osteonectin 
and N-propeptide alpha I type I collagen were upregulated in patients with 
periodontal disease. 
 In addition, the sites where the probing depth measures were 
increased, there was an elevation in the protein concentration in the GCF (3) .At 
the final analysis of this study, in comparison with the N-propeptide alpha I 
type I collagen ,osteonectin appeared to be the more sensitive marker for 
detection of periodontal disease status. 
GCF: 
            In 1899, Black was the first to report about the presence of a fluid in 
the periodontal sulcus. But, the exact nature of the fluid, its origin, and its 
composition has been controversial. Brill and Egelberg suggested that due to 
an increase in the permeability of the vessels underlying the junctional and 
sulcular epithelium GCF was produced, which might occur due to 
inflammation, trauma, or mechanical stimulation.  
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            Later, Alfano(5) suggested that the  GCF as the initial transudate fluid 
produced due to the  presence of highly osmotic substances in the gingival 
sulcus (bacterial products, plaque).  
            This hypothesis was supported by Pashley(102), who suggested that 
when the rate of capillary filtrate exceeds that of lymphatic uptake, fluid will 
accumulate as edema and/or leave the area as GCF.  The filtration coefficients 
of the capillary endothelium and the osmotic pressure within the different 
compartments are the factors which alter the process. 
  GCF is a serum transudate in a healthy state, and in pathological 
condition, a more inflammatory exudate from the vessels of gingival plexus 
and it is the part of gingival defence system, rich in leucocytes polymorpho 
nuclear neutrophils which is chemotactic gradient of bacterial/host origin.  
          It also has host-derived molecules from blood, micro-organisms from 
bacterial plaque (Ahlo-2007)(63). Ozkavaf et al stated that the GCF flow and 
volume increases during inflammation. 
In healthy sites, GCF flow is 3µl/h and 20µl/h for intermediate pockets 
and 44µl/h for deep pockets (27). 
Ng   et   al(95) analyzed   salivary   biomarkers related with alveolar 
bone loss. They found that several individual biomarkers were significantly 
related with bone loss score (IL-1β, IL-6, PGE2, osteonectin, and   
osteocalcin) but, multivariate analysis revealed that IL-1β and osteonectin 
were the only two biomarkers studied were increased in the bone loss. 
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         GCF continuously flush the dentogingival crevice and secrete the 
antimicrobial components of serum such as antibodies and complement 
enzymes. In disease, the crevicular fluid flow increases by 30 times more than 
in health. 
 The GCF is a reliable tool in active phase of the destructive disease. The 
presence of alkaline phosphatise, α glucoronidase, interleukins and 
prostaglandins are specific indicators for periodontal disease progression. 
[Bang et al 1970] and some enzymes are detected much earlier, before the 
diseased is established clinically. 
PISF 
  The long-term success of an osseointegrated implants depends on 
various factors which maintains the integrity of the peri-implant tissue. 
[James and lozada 1989](134). Anatomically, environmentally and 
functionally the peri implant sulcus is similar to the periodontal sulcus 
[berglundh et al 1991](8) and provides a medium for microbial colonisation. 
Peri-implant crevice is created surgically and the pocket depth is determined 
by various factors like abutment height, depth of fixture countersinking at 
stage-I surgery, the amount of tissue thinning during stage-II surgery. The 
reversible inflammation in response to the plaque accumulation is termed as 
periimplant mucositis, whereas the peri implantitis is irreversible 
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inflammatory reaction which involves the supporting bone around a functional 
implant. Thus, these peri implant diseases are recorded clinically by probing 
depth, gingival index, mobility and bleeding on probing and by radiographs. 
[Albrektsson et al 1986](1). But they do not explain either the disease 
progression or the current disease activity, they only infer the extent of the peri 
implant tissue lost. [Mombelli and Lang 1994] (89). 
  Though the radiographs can represent the bone loss, but they are seen 
only in the later stages of demineralization, thus the initial stages of the 
disease could not be screened. While looking upon the clinical evaluation like 
the probing depth and bleeding score, they depend on the skill of the examiner 
and could not be relied. [Errricson and Lindhe,1994](9). Moreover, the nature 
of the peri implant tissue varies from the periodontal tissue which allows the 
entry of the probe apically easily. [Mombelli et al 1997] (88). The bleeding on 
probing is not specific to the inflammation in the peri implant tissue. [erricson 
and lindhe](9), whereas the absence of the bleeding can be inferred has a 
clinical indicator for the peri-implant stability. Thus, simple and reliable 
clinical tests are required to detect the disease progression in the initial and 
reversible stages. [Mombelli and Lang 1994](94). 
Curtis et al. stated that "markers of disease" might encompass three separate 
categories: 
1. indicators of current disease activity; 
2. predictors of future disease progression; 
3. predictors of future disease initiation at currently healthy sites. 
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  The Peri implant Sulcular Fluid (PISF) is an osmotically mediated 
inflammatory exudates, it is upregulated in volume during inflammation and 
capillary permeability. They also detect the osseointegration and bone 
resorption to the occlusal loading of the prosthesis [Last et al]. As they present 
with abundant components in them they can be used to detect the disease in 
the initial and reversible stage [lang et al](28). 
  Thus, our study is to determine the biological changes occurring of 
bone biomarkers osteocalcin or ostenectin around healthy gingival tissue and 
peri implant tissue. 
RATIONALE FOR GCF / PISF SAMPLING  
 Various cellular and biochemical molecules associated with disease 
activity are present in GCF. Sampling of crevicular fluid has advantages that 
they are equivalent to drawing of blood. Its advantages are the site specificity, 
non-invasiveness, and comparatively easy to obtain. GCF an inflammatory 
exudate which reflects the ongoing events in the periodontal environment that 
produce it.  
GCF / PISF SAMPLING METHODS  
Using a variety of methods the collection of GCF can be accomplished, 
each with distinct advantages and disadvantages. Based on the objective of the 
study, the method is usually selected. For the collection of GCF three 
techniques are commonly used.  
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❖ Use of absorbing paper strips / points  
❖ Microcapillary pipettes  
❖ Intra crevicular washing 
Absorbing paper points / strips  
Brill and Krasse(1958)(100)were the first to use filter paper strips for the  
collection of  crevicular fluid. These paper strips are either placed within the 
sulcus (intrasulcular method) or at the entrance (extra sulcular method). By 
using filter paper strips volume of GCF collected can be determined by 
various methods - 
❖ Linear measurement of fluid migration on strip 
❖ Weighing the strip 
❖ Use of stains 
❖ Ninhydrin 
❖ Fluroscein administration to patient 2 hours before the GCF/PISF 
collection and strips are examined under UV light  
❖ Electronic measuring devices –Periotron, which allows quick and 
accurate measuring of GCF volume. 
Microcapillary method  
  The use of fixed volume micropipette permits the collection of fluid by 
capillarity. As the internal diameter is known, the volume of GCF collected 
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can be accurately determined by measuring the distance which the fluid has 
migrated. 
Gingival washing method 
In this method, an isotonic solution such as Hank’s balanced solution is 
perfused into the sulcus, usually a fixed volume or using a custom made 
acrylic stent which isolates gingival tissues from rest of the mouth. The fluid 
obtained represents the dilution of crevicular fluid. For harvesting cells from 
the gingival crevice this technique is more valuable. 
The crevicular fluid is collected by the above methods, depending on 
the analyte under investigation. The filter paper is used commonly for 
enzymes assays and microcapillary pipette for analysis of connective tissue 
metabolites. 
LIMITATIONS OF GCF SAMPLING  
1. Contamination  
  Blood, saliva or plaque can contaminate the GCF, which in turn affect 
both volume and quality of the substance sort out for in the fluid. 
2. Sampling time  
  While using filter paper strips it has to be left in place for 5 seconds. 
On the other hand, it is said that collecting a minimum volume has can take 
upto 20-30 min.  
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3. Volume determination: 
   The fluid from the filter paper evaporates, which is the primary 
problem, as the volume collected usually would be less than 1 µl.  
More powerful diagnostic tools for clinicians to optimize their treatment 
predictability are made possible through the recent advances. Though there are 
many difficulties, the use of oral fluid based diagnostics appears to be a 
promising tool for diagnosing periodontal disease and to prognosticate 
periodontal treatment outcomes. 
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MATERIALS AND METHODS 
 
 24 patients recruited from pool of patients referred for periodontal 
treatment to the Department of Periodontics, Ragas Dental College, Chennai 
of which 12 patients who were followed 6 months post loading of endosseous 
implants were included in the study. Patients were explained regarding the 
study procedure and written informed consent was obtained from those agreed 
to participate in this study. The patients were informed that this research work 
was in no way directly related to the therapy or cure of the disease. The study 
was undertaken following approval from the institutional review board. 
The patients were selected on the following criteria: 
Selection criteria: 
Group A: comprises of subjects exhibiting no signs of periodontal disease: 
absence of bleeding on probing; PPD ≤3mm and no clinical and radiographic 
evidence of attachment or bone loss. 
Group B: comprises of subjects with implant placed and loaded before 
6months exhibiting no signs of peri implant disease: absence of bleeding on 
probing and Peri implant pocket depth ≤4mm and no clinical and radiographic 
evidence of bone loss beyond the first thread of the implant. 
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INCLUSION CRITERIA 
• Age group between 20-65years of both genders 
• Systemically healthy individuals 
• Patient who are highly compliant and willing to participate and follow 
up overtime period  
 
EXCLUSION CRITERIA 
• Presence of active periodontal disease and   
• Patient with any systemic disease and patients who are under medication 
that interfere with the final treatment outcome 
• Patient with known risk factor and risk modifiers which can influence the 
overall outcome of the treatment were excluded from the study 
• Pregnant and lactating women 
• Patient on antibiotic therapy for the past 6months  
• Patient on radiotherapy  
 
CLINICAL EVALUATION 
 Clinical evaluation was done using mouth mirror, William’s 
periodontal probe and plastic probe with William’s markings. PDs were 
measured at six locations per tooth (mesial-buccal, midbuccal, distal-buccal, 
mesial-lingual, mid-lingual, and distal-lingual) using a probe. The probing 
depth and bleeding on probing was evaluated for tooth and implant site. 
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GINGIVAL CREVICULAR FLUID COLLECTION 
 The supragingival plaque was removed from the selected site, using an 
ultrasonic scaler tip, without touching the marginal gingiva to avoid 
contamination and blocking of microcapillary pipette. The site was then air 
dried and isolated with cotton rolls. GCF was collected from sites using          
1- 5μL calibrated volumetric microcapillary pipettes by placing the tip of the 
pipette extracrevicularly (unstimulated) for 5-20 min, a standardized volume 
of 5μL GCF was collected using the calibration on the micropipette (11). The 
collected GCF was immediately transferred to eppendrof vials containing 
200μL of elutionbuffer (50mM TrisHCl, 0.2M NaCl, 5mM CaCl2 & 0.01% 
Triton X-100 at pH 7.5) and stored at -70°C until the time of assay. 
PERI IMPLANT SULCULAR FLUID COLLECTION 
 The implant sites were then air dried and isolated with cotton rolls. 
PISF was collected from sites using 1- 5μL calibrated volumetric 
microcapillary pipettes by placing the tip of the pipette extracrevicularly 
(unstimulated) for 5-20min, a standardized volume of 5μL PISF was collected 
using the calibration on the micropipette. The collected PISF was immediately 
transferred to eppendrof vials containing 200μL of elution buffer (50mM 
TrisHCl, 0.2M NaCl, 5mM CaCl2& 0.01% Triton X-100 at pH 7.5)and stored 
at -70°C until the time of assay(90,108). 
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Armamentarium 
❖ 5µl calibrated volumetric microcapillary pipettes (Sigma Aldrich Company) 
❖ Autoclavable Eppendrof tubes (2mL) 
❖ Cotton rolls 
❖ Double sided cheek retractors 
❖ Refrigerator 
❖ Microtiter plate reader fitted with appropriate filters  
❖ 10, 50 and 100 adjustable single channel micropipettes with disposable tips 
REAGENTS:  
Sandwich Elisa Kits 
1. Bioassay Technology Laboratory Human Osteocalcin/Bone Gla 
Protein ELISA Kit 
2. Bioassay Technology Laboratory Human Osteonectin ELISA Kit 
 
Principle of the method 
The Osteocalcin and the Osteonectin ELISA kit used in the study is a 
solid phase sandwich ELISA for the in-vitro qualitative and quantitative 
determination of proteins in oral or biological fluid. A capture Antibody 
highly specific for the protein to be detected has been coated to the wells of 
the microtiter strip plate provided during manufacture. Binding of protein 
samples and known standards to the capture antibodies and subsequent 
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binding of the biotinylated a secondary antibody to the analyte is completed 
during the incubation period. Any excess unbound analyte and secondary 
antibody is removed. The HRP conjugate solution is then added to every well 
including the zero wells, following incubation excess conjugate is removed by 
careful washing. A chromogen substrate is added to the wells resulting in the 
progressive development of a blue coloured complex with the conjugate. The 
colour development is then stopped by the addition of acid turning the 
resultant final product yellow. The intensity of the produced coloured complex 
is directly proportional to the concentration of the protein present in the 
samples and standards. The absorbance of the colour complex is then 
measured and the generated OD values for each standard are plotted against 
expected concentration forming a standard curve. This standard curve can then 
be used to accurately determine the concentration of protein in the sample 
tested. 
 
ELISA KIT CONTENTS 
 Osteocalcin kit included 96 well microtiter strip plate, plastic plate 
covers, standard (100pg/ml), standard diluent, biotinylated human OT/BGP 
antibody, streptavidin-HRP, Wash buffer, substrate solution A, substrate 
solution B and stop reagent. 
Materials and Methods 
 
55 
 
 Osteonectin kit included 96 assay plates, standard solution, 
biotinylated human ON antibody, streptavidin-HRP, substrate solution A, 
substrate solution B, wash buffer and stop solution. 
ASSAY preparation for Osteocalcin ELISA Kit- For GCF and PISF 
samples: 
The number of microwell strips required to test the desired number of 
samples and appropriate number of wells needed for running zeros and 
standards were determined and the wash buffer and standard diluent buffer for 
IL-6 were prepared according to the instruction given by the manufacturer.  
Preparation of the standard for Osteocalcin: 
 Standard vials must be reconstituted with the volume of standard 
diluent shown on the vial immediately prior to use. 120µl of the standard 
(160ng/ml) with 120µl of standard diluent should be reconstituted to generate 
a 80ng/ml standard stock solution. Allow the standard to sit for 15 mins with 
gentle agitation prior to making dilutions. Prepare duplicate standard points by 
serially diluting the standard stock solution (80ng/ml) 1:2 with standard 
diluent to produce 40ng/ml, 20ng/ml, 10ng/ml and 5ng/ml solutions. Standard 
diluent serves as the zero standard. Any remaining solution should be frozen at 
-20 and used within one months 
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Preparation of wash water 
 Wash Buffer Dilute 20ml of Wash Buffer Concentrate 30x into 
deionized or distilled water to yield 500 ml of 1x Wash Buffer. If crystals have 
formed in the concentrate, mix gently until the crystals have completely 
dissolved. 
PREPARATION OF STREPTAVIDIN -HRP 
 5 μl of streptavidin is mixed with 0.5 mL of HRP diluent immediately 
before use. Further the HRP solution to volumes appropriate for the required 
number of wells is diluted in a clean glass vial. 
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METHOD 
Assay procedure for osteocalcin 
S.No Assay steps Details 
1 
Addition Prepare all reagents, standard solutions and samples as 
instructed. Bring all reagents to room temperature before use. 
2 
Addition Insert the strips in the frames for use. The unused strips should 
be stored at 2-8°C. 
3 
Addition Add 50μl standard to standard well. 
4 
Addition 
Add 40μl sample to sample wells and then add 10μl anti-
OT/BGP antibody to sample wells, and then add 50μl 
streptavidin-HRP to sample wells and standard wells. (Not 
blank control well）. 
5 
Incubation 
Mix well. Cover the plate with a sealer. Incubate 60 minutes 
at 37°C. 
6 
Wash 
Remove the sealer and wash the plate 5 times with wash 
buffer. Soak wells with at least 0.35 ml wash buffer for 30 
seconds to 1 minute for each wash. For automated washing, 
aspirate all wells and wash 5 times with wash buffer, 
overfilling wells with wash buffer. Blot the plate onto paper 
towels or other absorbent material. 
7 
Addition 
Add 50μl substrate solution A to each well and then add 50μl 
substrate solution B to each well. Incubate plate covered with 
a new sealer for 10 minutes at 37°Cin the dark. 
8 
Addition Add 50μl Stop Solution to each well, the blue colour will 
change into yellow immediately. 
9 
Determination 
Determine the optical density (OD value) of each well 
immediately using a microplate reader set to 450 nm within 30 
min after adding the stop solution. 
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Osteonectin reagent preparation 
All reagents should be brought to room temperature before use. 
 Standard reconstitute the 120µl of the standard (24ng/ml) with 120µl 
of standard diluent to generate a 12µg/ml standard stock solution. Allow the 
standard to sit for 15 mins with gentle agitation prior to making dilutions. 
Prepare duplicate standard points by serially diluting the standard stock 
solution (12µg/ml) 1:2 with standard diluent to produce 6µg/ml,0.75µg/ml 
solutions. Standard diluent serves as the zero standard. Any remaining solution 
should be frozen at -20°C and used within one month.  
Preparation of wash water 
 Wash Buffer Dilute 20ml of Wash Buffer Concentrate 30x into 
deionized or distilled water to yield 500 ml of 1x Wash Buffer. If crystals have 
formed in the concentrate, mix gently until the crystals have completely 
dissolved. 
PREPARATION OF STREPTAVIDIN -HRP 
 5 μl of streptavidin is mixed with 0.5 mL of HRP diluent immediately 
before use. Further the HRP solution to volumes appropriate for the required 
number of wells is diluted in a clean glass vial. 
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METHOD 
Assay procedure for Osteonectin: 
S.No Assay steps Details 
1 Addition 
Prepare all reagents, standard solutions and samples as 
instructed. Bring all reagents to room temperature before 
use. The assay is performed at room temperature. 
2 Addition 
Determine the number of strips required for the assay. 
Insert the strips in the frames for use. The unused strips 
should be stored at 2-8°C. 
3 Addition 
Add 50μl standard to standard well. Note: Don’t add 
antibody to standard well because the standard solution 
contains biotinylated antibody. 
4 Addition 
Add 40μl sample to sample wells and then add 10μl anti-
ON antibody to sample wells, then add 50μl streptavidin-
HRP to sample wells and standard wells. Not blank 
control well. 
5 Wash 
Remove the sealer and wash the plate 5 times with wash 
buffer. Soak wells with at least 0.35 ml wash buffer for 
30 seconds to 1 minute for each wash. For automated 
washing, aspirate all wells and wash 5 times with wash 
buffer, overfilling wells with wash buffer. Blot the plate 
onto paper towels or other absorbent material. 
6 
 
Addition 
Add 50μl substrate solution A to each well and then add 
50μl substrate solution B to each well. Incubate plate 
covered with a new sealer for 10 minutes at 37°Cin the 
dark. 
7 
 
Addition 
Add 50μl Stop Solution to each well, the blue colour will 
change into yellow immediately. 
8 Determination 
Determine the optical density (OD value) of each well 
immediately using a microplate reader set to 450 nm 
within 30 min after adding the stop solution. 
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STATISTICAL ANALYSIS: 
The Osteocalcin and Osteonectin results obtained were analysed statistically 
using the Mann-whitney U test and the independent t-test. P value ≤0.05 was 
considered to be statistically significant.  
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Fig. 1: HEALTHY GINGIVA (GROUP A) 
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Fig. 3: ARMAMENTARIUM FOR GINGIVAL CREVICULAR                 
FLUID COLLECTION 
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Fig. 5: GCF COLLECTION USING MICRO-PIPETTE (GROUP A) 
 
 
Fig. 6: PISF COLLECTION USING MICRO-PIPETTE (GROUP B) 
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Fig. 7: ELISA KIT FOR OSTEOCALCIN 
(Bioassay Technology Laboratory) 
 
 
Fig. 8: ELISA KIT FOR OSTEONECTIN 
(Bioassay Technology Laboratory) 
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Fig. 9: ARMAMENTARIUM FOR ELISA 
 
 
Fig. 10: ELISA AUTOMATED WASHER 
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Fig. 13: MICRO PLATE WELL DURING PROCEDURE 
 
 
 
Fig. 14: MICRO PLATE WELL AFTER STOP REAGENT 
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RESULTS 
 
The present study was done to evaluate the levels of osteocalcin and 
osteonectin in GCF in patients with healthy periodontal tissues and in the peri 
implant sulcular fluid in implant sites 6 months after loading. 
 12 GCF samples and 12 PISF samples were collected from the 
patients. Osteocalcin and Osteonectin levels were assessed using sandwich 
ELISA technique. Absorbance was measured at 450nm as primary wavelength 
in terms of pg/ml, and the results were obtained. 
Descriptive statistics included were the mean, standard deviation, 
minimum (min) and maximum(max). 
Evaluation of GCF and PISF levels of Osteocalcin in periodontal health 
 
 The levels of osteocalcin in the GCF of clinically healthy periodontium 
and in the PISF in peri implant health six months after loading in healthy 
subjects were evaluated. 
 There was a statistically significant increase in the osteocalcin levels in 
peri-implant fluid when compared to health. (Table 1)(Graph 1)  
 Since the data did not follow the normal distribution, the mean 
Osteocalcin levels in GCF and PISF was assessed using Mann Whiteny U test 
(Non-Parametric Data). 
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 The mean value of osteocalcin in 12 healthy subjects was observed to 
be 453.22 and the standard deviation was 205.19. In patients who underwent 
dental implants, the peri implant sites had a mean value of 2923.50 with a 
standard deviation of 2152.80. This gave a p value of 0.001 which was highly 
statistically significant. 
Evaluation of GCF and PISF levels of Osteonectin in periodontal health  
 
 The levels of osteonectin in the GCF of clinically healthy gingiva on 
an intact periodontium and in the PISF in peri implant health six months after 
loading in healthy subjects were evaluated. 
 There was an increase in the osteonectin levels in peri-implant fluid 
when compared to health but there was no statistically significant difference. 
(Table 2) (Graph 2) 
 The mean Osteonectin levels in GCF and PISF was assessed using 
independent ‘t’ test. 
 
The mean value of osteonectin in 12 healthy subjects was observed to 
be 268.92 and the standard deviation was 81.40. In patients who underwent 
dental implants, the peri implant sites had a mean value of 369.67 with a 
standard deviation of 255.07. This gave a p value of 0.206 which was not 
statistically significant. 
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Table 1.Mean Osteocalcin levels in the GCF and PISF in periodontal 
health using Mann Whiteny U test (Non-Parametric Data) 
 
 
       GRP N Mean Std. Deviation P 
OSTEOCALCIN 
HEALTHY 
PERIODONTIUM 12 453.22 205.19 
0.001 
PERI-IMPLANT 
HEALTH 12 2923.50 2152.80 
 
 
Graph 2:  LEVELS OF OSTEOCALCIN 
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Table 2.Mean Osteonectin levels in the GCF and PISF in periodontal 
health using using independent T test 
 
 GRP N Mean Std. Deviation P 
OSTEONECTIN 
HEALTHY 
PERIODONTIUM 12 268.92 81.40 
0.206 
PERI-IMPLANT 
HEALTH 12 369.67 255.07 
 
 
Graph 1:  LEVELS OF OSTEONECTIN 
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DISCUSSION 
 
 Physiological bone remodeling is a continually occurring process that 
occurs in a highly coordinated manner. This cycle operates continually as 
osteoclasts are constantly removing mature bone, with new bone 
simultaneously formed by osteoblasts (129). 
 A balance between the coupled processes of bone resorption by 
osteoclasts and bone formation by osteoblasts is essential for maintaining 
periodontal homoeostasis (16,128,129). 
 The overall quality and quantity of bone will be affected by any factor 
that influence either of these processes or perturb this balance. The hallmark 
of periodontal disease is alveolar bone loss and this occurs as a result of 
imbalance in the coupling/uncoupling mechanisms(50). Similarly, when an 
implant is placed, it involves of a series of events at the bone to implant 
interface for osseointegration to occur. Osseointegration is defined as a direct 
structural and functional connection between ordered, living bone and the 
surface of a load-carrying implant, it is critical for implant stability, and is 
considered a prerequisite for implant loading and long-term clinical success of 
end osseous dental implants(87). 
 Like periodontal health, the peri implant health around implants is also 
maintained in homeostasis via modeling and remodeling mechanisms(28). 
These processes are the two primary mechanisms by which bone at the 
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interface can adapt to mechanical loading, and thus are responsible for 
reshaping or consolidation of bone at the implant site(28). 
 Healing around an implant can be divided into two phases; namely the 
early and late phases. Upon placement of an implant, there is a response to a 
foreign material, namely, protein adsorption, platelet activation, clotting and 
inflammation. Early healing produces immature woven bone that fills the gap 
between the implant and bone via contact and distance osteogenesis, the later 
stages of healing comprise of the conversion of woven into lamellar bone(73). 
The remodeling of the peri implant bone continues for the life of the implant 
and is a complex process which involves the interactions between cells of 
alveolar bone and extracellular matrix components. 
 The diagnostic methods employed should provide the relevant 
information which aid to differentiate between different stages of periodontal 
disease, the degree of the destruction and the prognosis of the disease. The 
conventionally available clinical methods to evaluate the periodontal status 
like bleeding on probing, clinical attachment level and radiographs can only 
predict the destruction occurred previously but not the active disease 
progression(99). Similarly, in case of implant sites they also pose challenges 
like the force and direction of probing which differs between the individuals 
performing, implant and tooth morphology and the biotype of the surrounding 
tissues. Thus, there is considerable interest in developing diagnostics using the 
GCF and PISF as medium. 
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 A biomarker can be defined as an indicator of a biological state and 
can be used to distinguish between normal and pathologic processes (65). One 
of the main advantages of evaluating biomarkers from biofluids is the 
repeatability and non-invasive nature of obtaining samples for analysis. GCF 
represents a transudate of gingival tissue interstitial ﬂuid in health, but in the 
course of gingivitis and periodontitis, it is transformed into a true 
inﬂammatory exudate. Presence and functions of proteins, especially enzymes 
in GCF were ﬁrst explored by Sueda, Bang and Cimasoni(121). It was soon 
understood that enzymes released from inflamed periodontal tissue possessed 
an enormous potential for periodontal diagnosis. Similar expectations have 
been reported with the PISF obtained from the implant sites(31).  
 GCF and PISF from which the biomarkers are detected, which are the 
objective and measurable tools characteristic of the biological processes and 
are in close proximity to the inflamed sites (66). They also seem to be 
influenced more by the local reactions than the systemic inflammatory 
processes and thus they serve as a more accurate diagnostic tool.  
The present study was done to evaluate the levels of osteocalcin and 
osteonectin in the crevicular fluid of periodontally healthy tooth and in healthy 
peri implant site 6 months post loading. 24 sulcular fluid samples were 
collected i.e., the sulcular fluid was obtained from the gingival sulcus of the 12 
periodontally healthy subjects and from 12 peri-implant site between 20-65 
years of age, using micropipette. The samples collected were immediately 
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transferred to eppendroff vials which was stored at -70℃ and assessed with 
sandwhich ELISA.  
Solid-phase sandwich ELISA was performed to evaluate the GCF and 
PISF levels of osteocalcin and osteonectin. ELISA is known to be a sensitive 
method for protein quantification and it can be performed without undue cost 
and technical barriers. Point of Care application depends mainly on 
economically feasible technological tools so that vast populations can be 
surveyed simultaneously. 
ELISA was carried out according to the manufacturer’s instructions 
and the results of the GCF and PISF levels of osteocalcin and osteonectin are 
represented in table 1 and 2.  
Osteocalcin being a major non-collagenous matrix protein of bone, 
dentin, and cementum, is found in tight association with the calcium 
phosphate mineral phase of these tissues (60). In the presence of calcium, the 
Gla residues promote osteocalcin binding to hydroxyapatite and further 
accumulation in bone matrix. Osteocalcin secreted by osteoblast, is a crystal 
growth regulator as they interact specifically with the plane of grown crystals 
and they subsequently inhibit the crystal growth (111). 
The results of our study states that the Osteocalcin, the crystal growth 
regulators are significantly high around the implants after six months of 
implant loading when compared to periodontal health. In implant sites, the 
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process of contact osteogenesis is complete and is followed by the 
osseointegration by distant osteogenesis, where the remodeling is at its peak. 
Osteonectin has a diverse function in wide range of biological 
processes, such as development, differentiation, mineralization and tissue 
remodeling. Osteonectin is a de-adhesion matricellular protein (92) which aids 
the cell to move from a state of strong adherence to a state of weak adherence, 
which is also deemed necessary as this feature helps in the migration of the 
cells towards the implant, which in turn aids in the osseointegration and bone 
remodeling. Osteonectin is one such important matricellular protein that aids 
the cells to stay in spreaded morphology, antagonizing the pro-adhesive 
activity of other matrix proteins, which is very essential for cell proliferation 
occurring during any cellular injury (93). 
In our study there was an increase in the levels of osteonectin in the 
PSIF of implant, which are loaded before six months when compared to 
periodontal health. This supports its role as a bone turnover component and a 
deadhesion protein all signifying the process of distant osseointegration 
occurring around the implant. 
The clinical relevance of this study indicates that there is a always a 
constant remodeling mechanism which is occurring around an implant, as a 
result of which bone related glycoproteins are presumably expressed in higher 
levels in PISF when compared to GCF in periodontally healthy sites. The 
increase in the values of these non-collagenous proteins must not be inferred 
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as a state of peri implant disease. Also, a baseline normality range has to be 
established which may differ for individual implants. Hence, only sequential 
measurements made from the time of implant placement through loading and 
follow ups may help at arriving at the diagnosis if these bone related proteins 
are to be used as biomarkers of peri implant diseases.  
The results from our study suggests that the mean Osteocalcin was 
453.22 ± 205.19. Standard deviation and the mean osteonectin was 268.92 ± 
81.40 (Standard deviation) of GCF in periodontal health. 
  The large Standard deviation observed suggests that these is a 
considerable inter individual variability within the healthy group. The reason 
for this inter individual variation could be the differences in the masticatory 
load and stomatognathic system which in turn led to a considerable difference 
in the bone turnover among individuals. 
In case of subjects with implants placed, the mean osteocalcin was 
2923.50 ±, 2152.80 (Standard deviation) and the mean osteonectin was 369.67 
± 255.07 (Standard deviation) in PISF in peri implant health. This also 
exhibited a large standard deviation. 
The inter individual variation in the implant group was even higher 
than that observed in the tooth sites. 
These results suggest that, these is a greater variability in the bone 
turnover around implant when compared to natural tooth. In addition to the 
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masticatory load and the stomatognathic system that exists in natural teeth, the 
implant macro and micro design could have played a part in this variability in 
bone turnover (87).  
 
Limitations of the study include the following; 
(i) Sample size is relatively small, when we are trying to establish 
a baseline normal value. 
(ii) Only two biomarkers, osteonectin and osteocalcin were 
assessed. Analysis of a group of biomarkers may provide more 
meaningful information. 
 Further longitudinal studies with a large sample size conducted as 
biomarker arrays may be necessary to elucidate the role of bone turnover 
proteins as biomarkers in assessing the peri implant status. 
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DISCUSSION 
 
 Physiological bone remodeling is a continually occurring process that 
occurs in a highly coordinated manner. This cycle operates continually as 
osteoclasts are constantly removing mature bone, with new bone 
simultaneously formed by osteoblasts (129). 
 A balance between the coupled processes of bone resorption by 
osteoclasts and bone formation by osteoblasts is essential for maintaining 
periodontal homoeostasis (16,128,129). 
 The overall quality and quantity of bone will be affected by any factor 
that influence either of these processes or perturb this balance. The hallmark 
of periodontal disease is alveolar bone loss and this occurs as a result of 
imbalance in the coupling/uncoupling mechanisms(50). Similarly, when an 
implant is placed, it involves of a series of events at the bone to implant 
interface for osseointegration to occur. Osseointegration is defined as a direct 
structural and functional connection between ordered, living bone and the 
surface of a load-carrying implant, it is critical for implant stability, and is 
considered a prerequisite for implant loading and long-term clinical success of 
end osseous dental implants(87). 
 Like periodontal health, the peri implant health around implants is also 
maintained in homeostasis via modeling and remodeling mechanisms(28). 
These processes are the two primary mechanisms by which bone at the 
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interface can adapt to mechanical loading, and thus are responsible for 
reshaping or consolidation of bone at the implant site(28). 
 Healing around an implant can be divided into two phases; namely the 
early and late phases. Upon placement of an implant, there is a response to a 
foreign material, namely, protein adsorption, platelet activation, clotting and 
inflammation. Early healing produces immature woven bone that fills the gap 
between the implant and bone via contact and distance osteogenesis, the later 
stages of healing comprise of the conversion of woven into lamellar bone(73). 
The remodeling of the peri implant bone continues for the life of the implant 
and is a complex process which involves the interactions between cells of 
alveolar bone and extracellular matrix components. 
 The diagnostic methods employed should provide the relevant 
information which aid to differentiate between different stages of periodontal 
disease, the degree of the destruction and the prognosis of the disease. The 
conventionally available clinical methods to evaluate the periodontal status 
like bleeding on probing, clinical attachment level and radiographs can only 
predict the destruction occurred previously but not the active disease 
progression(99). Similarly, in case of implant sites they also pose challenges 
like the force and direction of probing which differs between the individuals 
performing, implant and tooth morphology and the biotype of the surrounding 
tissues. Thus, there is considerable interest in developing diagnostics using the 
GCF and PISF as medium. 
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 A biomarker can be defined as an indicator of a biological state and 
can be used to distinguish between normal and pathologic processes (65). One 
of the main advantages of evaluating biomarkers from biofluids is the 
repeatability and non-invasive nature of obtaining samples for analysis. GCF 
represents a transudate of gingival tissue interstitial ﬂuid in health, but in the 
course of gingivitis and periodontitis, it is transformed into a true 
inﬂammatory exudate. Presence and functions of proteins, especially enzymes 
in GCF were ﬁrst explored by Sueda, Bang and Cimasoni(121). It was soon 
understood that enzymes released from inflamed periodontal tissue possessed 
an enormous potential for periodontal diagnosis. Similar expectations have 
been reported with the PISF obtained from the implant sites(31).  
 GCF and PISF from which the biomarkers are detected, which are the 
objective and measurable tools characteristic of the biological processes and 
are in close proximity to the inflamed sites (66). They also seem to be 
influenced more by the local reactions than the systemic inflammatory 
processes and thus they serve as a more accurate diagnostic tool.  
The present study was done to evaluate the levels of osteocalcin and 
osteonectin in the crevicular fluid of periodontally healthy tooth and in healthy 
peri implant site 6 months post loading. 24 sulcular fluid samples were 
collected i.e., the sulcular fluid was obtained from the gingival sulcus of the 12 
periodontally healthy subjects and from 12 peri-implant site between 20-65 
years of age, using micropipette. The samples collected were immediately 
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transferred to eppendroff vials which was stored at -70℃ and assessed with 
sandwhich ELISA.  
Solid-phase sandwich ELISA was performed to evaluate the GCF and 
PISF levels of osteocalcin and osteonectin. ELISA is known to be a sensitive 
method for protein quantification and it can be performed without undue cost 
and technical barriers. Point of Care application depends mainly on 
economically feasible technological tools so that vast populations can be 
surveyed simultaneously. 
ELISA was carried out according to the manufacturer’s instructions 
and the results of the GCF and PISF levels of osteocalcin and osteonectin are 
represented in table 1 and 2.  
Osteocalcin being a major non-collagenous matrix protein of bone, 
dentin, and cementum, is found in tight association with the calcium 
phosphate mineral phase of these tissues (60). In the presence of calcium, the 
Gla residues promote osteocalcin binding to hydroxyapatite and further 
accumulation in bone matrix. Osteocalcin secreted by osteoblast, is a crystal 
growth regulator as they interact specifically with the plane of grown crystals 
and they subsequently inhibit the crystal growth (111). 
The results of our study states that the Osteocalcin, the crystal growth 
regulators are significantly high around the implants after six months of 
implant loading when compared to periodontal health. In implant sites, the 
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process of contact osteogenesis is complete and is followed by the 
osseointegration by distant osteogenesis, where the remodeling is at its peak. 
Osteonectin has a diverse function in wide range of biological 
processes, such as development, differentiation, mineralization and tissue 
remodeling. Osteonectin is a de-adhesion matricellular protein (92) which aids 
the cell to move from a state of strong adherence to a state of weak adherence, 
which is also deemed necessary as this feature helps in the migration of the 
cells towards the implant, which in turn aids in the osseointegration and bone 
remodeling. Osteonectin is one such important matricellular protein that aids 
the cells to stay in spreaded morphology, antagonizing the pro-adhesive 
activity of other matrix proteins, which is very essential for cell proliferation 
occurring during any cellular injury (93). 
In our study there was an increase in the levels of osteonectin in the 
PSIF of implant, which are loaded before six months when compared to 
periodontal health. This supports its role as a bone turnover component and a 
deadhesion protein all signifying the process of distant osseointegration 
occurring around the implant. 
The clinical relevance of this study indicates that there is a always a 
constant remodeling mechanism which is occurring around an implant, as a 
result of which bone related glycoproteins are presumably expressed in higher 
levels in PISF when compared to GCF in periodontally healthy sites. The 
increase in the values of these non-collagenous proteins must not be inferred 
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as a state of peri implant disease. Also, a baseline normality range has to be 
established which may differ for individual implants. Hence, only sequential 
measurements made from the time of implant placement through loading and 
follow ups may help at arriving at the diagnosis if these bone related proteins 
are to be used as biomarkers of peri implant diseases.  
The results from our study suggests that the mean Osteocalcin was 
453.22 ± 205.19. Standard deviation and the mean osteonectin was 268.92 ± 
81.40 (Standard deviation) of GCF in periodontal health. 
  The large Standard deviation observed suggests that these is a 
considerable inter individual variability within the healthy group. The reason 
for this inter individual variation could be the differences in the masticatory 
load and stomatognathic system which in turn led to a considerable difference 
in the bone turnover among individuals. 
In case of subjects with implants placed, the mean osteocalcin was 
2923.50 ±, 2152.80 (Standard deviation) and the mean osteonectin was 369.67 
± 255.07 (Standard deviation) in PISF in peri implant health. This also 
exhibited a large standard deviation. 
The inter individual variation in the implant group was even higher 
than that observed in the tooth sites. 
These results suggest that, these is a greater variability in the bone 
turnover around implant when compared to natural tooth. In addition to the 
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masticatory load and the stomatognathic system that exists in natural teeth, the 
implant macro and micro design could have played a part in this variability in 
bone turnover (87).  
 
Limitations of the study include the following; 
(i) Sample size is relatively small, when we are trying to establish 
a baseline normal value. 
(ii) Only two biomarkers, osteonectin and osteocalcin were 
assessed. Analysis of a group of biomarkers may provide more 
meaningful information. 
 Further longitudinal studies with a large sample size conducted as 
biomarker arrays may be necessary to elucidate the role of bone turnover 
proteins as biomarkers in assessing the peri implant status. 
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SUMMARY AND CONCLUSION 
 
The aim of the present was to evaluate the levels of osteocalcin and 
osteonectin obtained from the peri implant sulcular region around endosseous 
implants 6 months post loading.  
24 patients who reported to out-patient Department of Periodontology, 
Ragas Dental College and Hospitals, Chennai were enrolled in the study. 
These patients were divided into two groups, 12 samples were obtained from 
the periodontally healthy subjects and 12 samples were obtained from the peri 
implant sulcular region of the implant which is loaded before six months. GCF 
and PISF samples were collected and analysed for osteocalcin and osteonectin 
using sandwich ELISA technique. Statistical analysis was done using Mann 
Whitney U test and independent t test. 
Based on the results of the study, we may conclude that: 
1. There was a statistically significant increase in the levels of osteocalcin 
and osteonectin in peri-implant sulcular fluid compared to GCF in 
periodontal health. This maybe a result of active bone remodeling taking 
place around the implant due to distant osteogenesis.  
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2. This increase in the osteocalcin and osteonectin levels implicates the need 
for establishing a baseline normal value in health and the importance of 
their sequential measurements to assess the underlying pathobiology.  
Further longitudinal studies conducted as biomarker arrays on a larger 
population may be necessary to elucidate the role of bone turnover proteins as 
biomarkers in assessing the peri implant status and in affirming our results. 
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ANNEXURE – III 
 
 
CONSENT FORM 
I ……………………………………………………S/o, w/o, 
d/o………………………  
aged about ……………….years, Hindu/Christian/Muslim 
……………………………… ………….residing at 
…………………………………………………………………………do solemnly  
And state as follows.  
I am the deponent herein; as such I am aware of the facts stated here under  
I state that I came to Ragas Dental College and Hospital, Chennai for my 
treatment for  
……………………………………………………………………………………
…………………………  
I was examined by Dr……………………………………….. and I was requested 
to do the following  
1. Full mouth Plaque Score  
2. Full mouth bleeding score  
3 Measurement of periodontal pocket depth and clinical attachment loss 
   Annexures 
 
 
 
I was also informed and explained about the collection of plaque during scaling in 
…………………………………(language) known to me.  
I was also informed and explained that the results of the individual test will not be 
revealed to the public. I give my consent after knowing full consequence of the 
dissertation/thesis/study and I undertake to cooperate with the doctor for the 
study.  
I also authorise the Doctor to proceed with further treatment or any other suitable 
alternative method for the study,  
I have given voluntary consent to the collection of plaque for approved research.  
I am also aware that I am free to withdraw the consent given at any time during 
the study in writing.  
Signature of the patient/Attendant  
The patient was explained the procedure by me and has understood the same and 
with full consent signed in (English/Tamil/Hindi/Telugu?.............................) 
before me  
 
Signature of the Doctor 
 
